Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent with the capability of inducing apoptosis specifically in tumor cells. However, cancer cells of many cancer types developed TRAIL resistance, limiting the applications of TRAIL in cancer therapies. We show here that p68 acquires a double tyrosine phosphorylation at Y593 and Y595 in TRAIL-resistant T98G glioblastoma cells. The double phosphorylations are induced by platelet-derived growth factor autocrine loop. The double phosphorylation mediates resistance to TRAIL-induced apoptosis. Our data suggest that the phosphorylated p68 protects the cells from programmed cell death by preventing procaspase-8 from proteolytic cleavage. The double-phosphorylated p68 may also confer apoptosis resistance by upregulation of X-chromosome-linked inhibitor apoptosis protein-associated factor 1. In addition, exogenous expression of p68 mutant that carries mutations at the phosphorylation sites (Y593/595F) dramatically sensitizes TRAIL-resistant cells to TRAIL-induced apoptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines. TRAIL has the unique property of inducing apoptosis in certain cancer cells but not in most normal cells (Bouralexis et al., 2005; Clarke et al., 2005) . Although the mechanism underlying the tumor-specific apoptosis induction is not fully understood, this property makes TRAIL a very promising tumor-specific anticancer agent. However, many human cancer cells are resistant to TRAIL-induced apoptosis, which largely limits the use of TRAIL as an effective antitumor drug (Zhang and Fang, 2005) .
TRAIL is a transmembrane protein. The extracellular termini interact with each other to form a trimer. TRAIL induces cell apoptosis through binding to its cellular receptors (Griffith and Lynch, 1998; Yagita et al., 2004) . Upon binding to trimeric TRAIL, the TRAIL receptors (DR4 and DR5) recruit Fas-associated death domain (FADD) and procaspases-8 to form the death-induced signaling complex (DISC). The formation of DISC triggers the activation of autoproteolytic activity, which activates caspase-8 (Kim and Seol, 2003; Aggarwal et al., 2004; Thorburn, 2004) , and subsequently activates the downstream caspase-3, which in turn leads to apoptosis (Wang and Lenardo, 2000; Boatright and Salvesen, 2003) . A number of antiapoptotic pathways counteract this death-inducing signal (Grotzer et al., 2000; Nesterov et al., 2001; Deng et al., 2002; LeBlanc et al., 2002; Yang et al., 2003; Roth and Reed, 2004; Van Geelen et al., 2004) . Among the many mechanisms that confer TRAIL resistance, expression of inhibitor apoptosis proteins (IAPs) constitutes an important pathway for anti-TRAILinduced apoptosis. The X-chromosome-linked IAP (XIAP) is a typical member of the IAP family. XIAP can directly bind to caspase-3, -7 and -9. The consequence of the interaction is the inhibition of the activities of the caspases (Holcik et al., 2001) . Interestingly, cells express another factor, XIAP-associated factor 1 (XAF1), to neutralize the effects of XIAP. XAF1 binds XIAP and redistributes the XIAP to the cell nucleus. The cytosolic caspases are released and subsequently trigger apoptosis (Liston et al., 2001; Leaman et al., 2002) . However, the expression of XAF1 is suppressed in most cancer cells, especially in the cancer cells of many aggressive cancers (Fong et al., 2000; Ng et al., 2004) .
The nuclear p68 RNA helicase is a prototypical member of the DEAD box family of RNA helicase (Lane and Hoeffler, 1980; Crawford et al., 1982) . P68 RNA helicase plays a very important role in cell proliferation and early organ development and maturation (Stevenson et al., 1998) . The expression of the protein was shown to correlate with tumor progression and transformation (Causevic et al., 2001) . We have previously reported that p68 RNA helicase is Tyrosine phosphorylations of expressed HA-p68s (wt, Y593F, Y595F or Y595/595F) in T98G cells were detected by IB using antibody p-Tyr-100 (the third panel). The HA-p68s were IP from nuclear extracts by anti-HA antibody. The IB via antibodies p68-rgg (upper panel) and against actin (bottom panel) are loading controls. The endogenous p68 was knocked down by small interfering RNA (siRNA) against p68 (p68) or cells were treated with NT. (c) MALDI MS of CNBr-cleaved endogenous p68 immunoprecipitated from nuclear extracts of T98G cells. (d) MALDI MS of CNBr-cleaved p68 purified from T98G cells. The peptide mixture was treated with; no treatment (input), purified by Pi 3 phosphotyrosine QE kit (Pi 3 phosphotyrosine QE), protein tyrosine phosphatase after Pi 3 purification (PTP), PP2A after Pi 3 purification (PP2A). (e) P68 CNBr cleavage peptides recovered from MALDI spectrum. MW Obs and Calcd are the observed or calculated molecular weight, respectively. p68 phosphorylation mediates apoptosis resistance L Yang et al phosphorylated at multiple amino-acid residues, including serine/threonine and tyrosine (Yang et al., 2005) . P68 was phosphorylated at tyrosine residue(s) in a number of different cancer cell lines but not in the corresponding normal cells/tissues. In response to platelet-derived growth factor-BB (PDGF-BB) stimulation, p68 is phosphorylated at Y593 by c-Abl in HT-29 cells. Phosphorylation of p68 at Y593 promotes Epithelial-Mesenchymal transition (EMT) via promoting b-catenin nuclear translocation (Yang et al., 2006) . We show here that p68 acquires a double tyrosine phosphorylation at Y593/Y595 in T98G glioblastoma cells. The double phosphorylations are likely induced by PDGF autocrine stimulation. The double phosphorylation mediates resistance to TRAIL-induced apoptosis. Our data suggest that the phosphorylated p68 protects the cells from programmed cell death by preventing procaspase-8 from proteolytic cleavage and activation. The double-phosphorylated p68 may also confer apoptosis resistance by upregulation of XAF1. Interestingly, our studies showed that exogenous expression of p68 mutant Y593/595F dramatically sensitizes TRAILresistant cells to TRAIL-induced apoptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.
Results
PDGF autocrine induce double phosphorylation of p68 at Y593 and Y595 in T98G cells We previously reported that tyrosine phosphorylation of p68 correlates with tumor progression (Yang et al., 2005) . In screening cancer cell lines for the correlation between the phosphorylation status of p68 and tumor progression, we noted that significantly higher levels of p68 tyrosine phosphorylation were observed in the glioblastoma cell line T98G (Yang et al., 2005) , although p68 was not tyrosyl phosphorylated in normal brain tissue and another glioma cell line, LN-18 ( Figure 1a ). We previously demonstrated that p68 RNA helicase became phosphorylated at Y593 in HT-29 and HCT-116 cells by c-Abl upon PDGF treatments (Yang et al., 2006) . We asked whether p68 is similarly phosphorylated at Y593 in T98G cells. We tested this speculation by expressing HA-p68s wild type (wt) and mutant (Y593F) in T98G cells in which the endogenous p68 was knocked down by RNA interference (RNAi). The exogenously expressed proteins were immunoprecipitated by hemagglutinin (HA)-tag antibody. Tyrosine phosphorylation levels were then examined by immunoblot using antibody against phosphortyrosine p-Tyr-100 (Yang et al., 2006) . HA-p68 (wt) was tyrosyl phosphorylated at a very high level. In contrast to our previous observations with HT-29 cells under PDGF treatment, tyrosine phosphorylation of the HA-Y593F mutant was significantly decreased but not diminished (Figure 1b) . We carried out the same experiments with other two mutants Y595F and Y593/595F (double mutations). Similarly, tyrosine phosphorylation of the Y595F mutant was decreased but not diminished. However, no phosphorylation was detected with the Y593/595F (Figure 1b) . These results indicated that p68 RNA helicase might be phosphorylated at Y593 and Y595 residues.
To confirm further the tyrosine phosphorylation sites in T98G cells, we employed matrix-assisted laser desorption ionization (MALDI) mass spectroscopy (MS) to verify the phosphorylation site(s). The cellular p68 was immunopurified from the nuclear extracts. The purified p68 was cleaved by CNBr. MS spectrum revealed a m/z 1600.25 Da peak that corresponded to an 80 Da shift of the m/z 1520.31 Da fragment. Interestingly, there was a m/z 1680.13 Da peak corresponding to an additional 80 Da shift (Figure 1c) . Both m/z 1598.58 and 1678.62 peaks could be purified by a Pi3 phosphotyrosine column. Further, these two shifts were sensitive to tyrosine phosphatase 1B (PTP) treatment (Figure 1d ), indicating that the shifts were indeed owing to tyrosine phosphorylation. The 1520.31 Da fragment is amino acids 589-603 ( Figure 1e ). There are two tyrosine residues in the fragment (Y593, Y595). Thus, MALDI MS confirmed that p68 was phosphorylated at Y593 and Y595 in T98G cells. The MS also clearly indicated that there were both single-phosphorylated p68 (1600.25 Da) and doublephosphorylated p68 (1680.13 Da). Currently, it is very difficult to determine the ratio of single/doublephosphorylated p68 in cells. However, it is likely that both single-and double-phosphorylated p68s were in similar levels judging by the intensity of the m/z peaks. We next investigated the cellular signaling pathway that induced p68 phosphorylation at Y593 and Y595 in T98G cells. We previously showed that p68 can be phosphorylated at Y593 under stimulation of PDGF (Yang et al., 2006) . On the other hand, it is well known that T98G cells have a strong PDGF autocrine loop with the PDGF-AA and PDGF receptor-a (PDGFRa) (Potapova et al., 1996; Takeuchi et al., 2004) . Thus, we sought to test whether the PDGF autocrine-induced p68 double phosphorylation. We first disrupted the PDGF autocrine by knockdown of PDGFRa using RNAi. Immunoblot analyses showed that the cellular levels of the receptor decreased dramatically (B85%), whereas the expression levels of p68 and another housekeeping gene actin were not affected by the RNAi treatments ( Figure 2a) . Examination of the tyrosine phosphorylation of p68 demonstrated that the p68 tyrosine phosphorylation was almost completely abolished by the RNAi treatment (Figure 2a ). To prove further that the PDGF autocrine induced the tyrosine phosphorylation of p68 in T98G cells, we used an antibody against PDGF-AA in the cell culture medium to neutralize the secreted growth factor. It was evident that the antibody in the medium blocked the PDGFRa activation as revealed by the disappearance of the phosphorylation of PDGFRa at Y572/574 (Hwang et al., 2003) . Under these conditions, p68 was not phosphorylated at tyrosine in the treated T98G cells (Figure 2b ). Thus, our experiments suggested that the PDGF autocrineinduced p68 phosphorylation at Y593 and Y595 in T98G cells.
The Y593/595 phosphorylations of p68 mediated resistance to Trail-induced apoptosis Phosphorylation of p68 at Y593 mediates cell proliferation and EMT (Yang et al., 2006) . We investigated functional role of Y593/595 double-phosphorylated p68 in T98G cells. T98G cell line is a glioblastoma cell line with high proliferation capability and strong resistance to TRAIL-induced apoptosis (Hao et al., 2001; Bockbrader et al., 2005) . Although p68 was highly phosphorylated at tyrosine residues in T98G cells, p68 was not phosphorylated in another tested TRAIL-sensitive glioblastoma cell line LN18 (Hao et al., 2001) (Figure 1a) . In our previous studies, we observed that p68 became dephosphorylated at tyrosine in a number of cancer cell lines upon TRAIL treatments (Yang et al., 2005) . However, p68 was not dephosphorylated at tyrosine in T98G cells upon TRAIL treatment (Figure 3a) . Persistent phosphorylation of p68 after TRAIL treatment was also observed with several other TRAIL-resistant cell lines (data not shown). Thus, we suspected that the double phosphorylation of p68 might mediate resistance to TRAIL-induced apoptosis. To test this conjecture, we examined the apoptosis of T98G cells under TRAIL treatments. The p68 was knocked down and the HA-p68s (wt or Y593/595F) were expressed in the cells. Microscopic examination of the cells revealed that knockdown of p68 led to cell rounding (indication of apoptosis) in a significant portion of the cells. The cells were protected from TRAIL-induced apoptosis (rounding) by expression of HA-p68 (wt). Interestingly, expression of the Y593/595F mutant in p68 knockdown cells resulted in even more cell rounding upon TRAIL treatment (Figure 3b ). We also carried out an apoptosis assay with the similarly TRAIL-treated T98G cells using Trypan blue staining. Knockdown of p68 led to more than double population of apoptotic cells under the treatment of 50 ng/ml TRAIL. Expression of the Y593/ 595F mutant resulted in an additional double number of cells that underwent apoptosis (Figure 3c ).
To confirm further the role of the double tyrosine phosphorylation of p68 on TRAIL resistance, we examined tyrosine phosphorylation of p68 in two pairs of cell lines. The parental cells, H460 and HCT-116, are sensitive to TRAIL treatment. The derivative cell lines, H460R and HCT-116R, are TRAIL resistant (see Materials and methods section). P68 RNA helicase was immunoprecipitated from nuclear extracts made from these four cell lines. Tyrosine phosphorylation of p68 was examined by immunoblot using antibody p-Tyr-100. P68 was phosphorylated at tyrosine residues at very low levels in TRAIL-sensitive cells, H460 and HCT-116. However, the tyrosine phosphorylation of p68 was dramatically increased in both TRAIL-resistant cell lines (Figure 4a ). To test whether p68 indeed had a role in the TRAIL resistance of the engineered cell lines, we monitored the responses of HCT-116R to TRAIL treatment under the condition that p68 RNA helicase was knocked down by RNAi. The apoptotic and viable cells under TRAIL treatment were measured DNA fragmentation. It was clear that knockdown of p68 dramatically sensitized HCT-116R to TRAIL treatment (Figure 4b ), indicating that p68 did mediate the TRAIL resistance.
The double tyrosine phosphorylation of p68 inhibits procaspase-8 cleavage and suppresses XAF1 expression To delineate the molecular mechanism by which the double tyrosine phosphorylated p68 confers TRAIL resistance, we examined the activation of caspase-3 after TRAIL treatment in T98G cells by immunostaining using antibody against the activated caspase-3. Endogenous p68 was knocked down and HA-p68s (wt or Y593/595F mutant) were expressed in the cells. TRAIL treatment resulted in very little caspase-3 activation in cells in which p68 was not knocked down. Knockdown of p68 led to substantial caspase-3 activation under the TRAIL treatment. Expression of wt p68 restored the inactivation of caspase-3. However, caspase-3 was even more dramatically activated when the Y593/595F mutant was expressed in the p68 knockdown cells (Figure 5a ). It was noted that p68 knockdown or expression of the Y593/595F alone without TRAIL treatment did not activate caspase-3 (Figure 5a ), suggesting that p68 knockdown or expression of the Y593/ 595F did not cause cell death. In the TRAIL-induced apoptosis pathway, pre-caspase-3 proteolytically p68 phosphorylation mediates apoptosis resistance L Yang et al cleaves/activates the activated caspase-8 (Kim and Seol, 2003; Aggarwal et al., 2004; Thorburn, 2004) . We therefore tested whether the activation of caspase-8 was affected by p68 phosphorylation. HA-p68s (wt or Y593/595F) were transiently expressed in the T98G cells. The cells were treated/untreated with TRAIL. The cleavage products of procaspase-8, p43/p41 and p18, were examined by immunoblotting. Clearly, under the TRAIL treatment, expression of wt p68 did not lead to the procaspase-8 cleavage. However, transient expression of the Y593/595F led to high levels of procaspase-8 cleavage (Figure 5b ). PARP-1 is cleaved by caspase-3 or -7 Figure 3 Phosphorylation of P68 at Y593/Y595 mediates resistance to TRAIL-induced apoptosis. (a) Tyrosine phosphorylation of p68 in T98G cells treated/untreated ( þ /À) with 50 ng/ml TRAIL. P68 was immunoprecipitated (IP:PAbp68) from nuclear extracts and followed by IB with appropriate antibody (indicated). P68 was knocked down (p68 siRNA/NT). HA-p68s (wt or Y593/595F mutant) were expressed. The IB:H2A is a loading control. (b) The morphologies of T98G cells were revealed by phase-contrast microscopy. The cells were treated/untreated ( þ /À) with 50 ng/ml of TRAIL. P68 was knocked down (p68 siRNA/NT). HA-p68s (WT or Y593/595F mutant) was expressed. The arrows indicate the rounded cells. (c) Apoptosis of T98G cells under the treatment/untreatment (filled bars/open bars) of 50 ng/ml of TRAIL was analysed by a Trypan blue staining. P68 was knocked down by siRNA against p68 (p68) or cells were treated with NT. HA-p68s (wt or Y593/595F mutant) was exogenously expressed. The percent of apoptotic cells was based on counting the Trypan blue-stained cells.
p68 phosphorylation mediates apoptosis resistance L Yang et al in the apoptosis-induced cells (Soldani and Scovassi, 2002) . Our data also showed the cleavage of PARP-1 in the Y593/595F mutant-expressing cells under TRAIL treatment (Figure 5b ). Thus, our data indicated that the tyrosine phosphorylation of p68 may mediate TRAIL resistance by inhibition of caspase-8 activation.
In screening for the other potential molecules that might mediate the effects of the phosphorylated p68, we carried out a gene array analysis in p68 knockdown HeLa cells. The expression of many genes was affected by p68 knockdown (data not shown). We noticed that expression of XAF1 was almost fourfold increased (Figure 6a ). To test whether expression of XAF1 was regulated by the p68 phosphorylation in T98G cells, we examined cellular levels of XAF1 in the cells in which the p68 was knocked down and HA-p68s (wt and mutants) were expressed. It was clear that XAF1 was slightly increased in p68 knockdown cells. Expression of p68 (wt) re-suppressed XAF1 expression. However, expression of the Y593/595F dramatically increased the cellular levels of XAF1. We reasoned that downregulation of XAF1 might account for the effects of the double-phosphorylated p68 on TRAIL resistance. To test this conjecture, XAF1 was knocked down by RNAi in T98G cells in which the HAp68s (wt or Y593/595F) was expressed. Apoptosis of the cells was then monitored. When the Y593/595F was expressed, XAF1 was expressed in a high level and the Y593/595F-expressing T98G cells were very sensitive to TRAIL treatment. However, when XAF1 was knocked down, the sensitivity of the Y593/595F-expressing cells to TRAIL treatment was dramatically decreased, suggesting that expression of XAF1 indeed mediated the effects of the Y593/Y595F mutations in sensitizing T98G cells to TRAIL-induced apoptosis (Figure 6b) . However, the apoptosis levels did not decrease to the same level of T98G cells without expression of the Y593/595F mutant (44 vs 10% apoptotic cells). The results indicated that upregulation of XAF1 is not the sole reason for the TRAIL sensitization by the p68 Y593/Y595F mutations.
Discussion
In this report, we describe that p68 RNA helicase is phosphorylated at Y593 and Y595 in T98G glioblastoma cells. The double phosphorylations are induced by PDGF autocrine loop. Phosphorylation of p68 at Y593 and Y595 mediated resistance of the cells to Figure 4 P68 is phosphorylated and is required for TRAIL resistance. (a) Tyrosine phosphorylation of p68 RNA helicase in two TRAIL sensitive (S) H460 and HCT116 cell lines and two engineered TRAIL-resistant (R) H460 and HCT116 cell lines. P68 was immunoprecipitated (IP:PAbp68) from nuclear extracts and followed by IB with appropriate antibody (indicated). The IB:p68-rgg is a loading control. (b) P68 is required for TRAIL resistance of HCT-116R cells. Upper panel, the p68 expression in HCT-116R cells that were treated by siRNA against p68 (p68) or NT was examined by IB with antibody p68-rgg. IB:H2A is a loading control. Lower panel, the 'TdT-mediated dUTP nick end labeling' (TUNEL) assay of the apoptosis of HCT-116R cells under the treatment of 10 ng/ml of TRAIL. P68 was knocked down by siRNA against p68 (p68 siRNA) or cells were treated with NT siRNA. The number on the right is the percentage of apoptotic cells and the number on the left is the percentage of surviving cells.
p68 phosphorylation mediates apoptosis resistance L Yang et al TRAIL-induced apoptosis. Our data showed that the double-phosphorylated p68 mediates TRAIL resistance by inhibiting the activation of caspase-8 and the subsequent activation of caspase-3. Interestingly, the phosphorylated p68 also played a role in regulating the expression of XAF1. Our experiments demonstrated that regulating the expression of XAF1 by the phosphorylated p68 contributed, at least partially, to the resistance to TRAIL-induced apoptosis in T98G cells. We previously demonstrated that p68 was phosphorylated at Y593 in HT-29 cells in response to PDGF-BB treatments. PDGF treatment activated c-Abl, which subsequently phosphorylated p68 (Yang et al., 2006) . Several lines of evidence suggested that p68 may also be phosphorylated by c-Abl at Y593 and Y595 in T98G cells. Firstly, c-Abl kinase is constitutively activated in T98G cells as demonstrated by the phosphorylation of c-Abl at Y245 (Figure 2c) . Secondly, RNAi knockdown of c-Abl (B85%) almost abolished p68 tyrosine phosphorylation in T98G cells (Figure 2d ). Thirdly, a peptide that spans amino-acid sequence of 589-601 of p68 can be phosphorylated by a recombinant c-Abl at both Y593 and Y595 residues in vitro as revealed by MS of the peptide before and after phosphorylation (Figure 2e ). Careful examination of the sequence revealed that Y595 may also be a potential c-Abl phosphorylation site. Why only Y593 is phosphorylated in PDGF-BB-treated HT-29 cells, although both Y593 and Y595 are phosphorylated in T98G cells? One possible explanation would be that an active PDGF autocrine loop leads to the double phosphorylation. Unlike the case of stimulation of HT-29 cells by PDGF, whereby c-Abl is transiently activated, PDGF autocrine in T98G may lead to a constantly activated c-Abl, which may phosphorylate p68 at an additional Y595 site (a suboptimal site). Alternatively, differential phosphorylations of p68 may be owing to different actions of PDGF and receptor isoforms.
The downstream cellular targets of the Y593-or the Y593/595-phosphorylated p68 also seem to be different. One main action of the Y593-phosphorylated p68 in PDGF-stimulated HT-29 cells is to promote b-catenin Figure 5 Activity of caspase-3 and -8 are regulated by the phosphorylation of p68 at Y593/595. (a) Immunofluorescence staining of caspase-3 in T98G cells using antibody against activated caspase-3. The cells were treated/untreated with 50 ng/ml TRAIL. P68 was knocked down by siRNA (p68) or the cells were treated with NT. HA-p68s (wt or Y593/595F mutant) was overexpressed in the p68 knockdown cells. The red signal represents staining of cleaved/activated caspase-3. (b) Immunoblotting analyses of cleavage of procaspase-8 and PARP-1 in T98G cells with/without ( þ /À) 50 ng/ml TRAIL treatment. The procaspase-8 and the cleaved caspase-8 (p43/p41 or p18) were detected by IB using antibody1C12 (IB:1C12). The cleaved PARP-1 was detected by IB using antibody 19F4 (IB:19F4) . IB of actin (IB:Actin) is a loading control. HA-p68s (wt or Y593/595F mutant) was overexpressed in the T98G cells.
p68 phosphorylation mediates apoptosis resistance L Yang et al nuclear translocation (Yang et al., 2006) . However, no strong co-immunoprecipitation of the Y593/595-phosphorylated p68 with b-catenin was detected in T98G cells (data not shown), which indicates that the doublephosphorylated p68 may target different molecule(s) and consequently lead to different events in the cells. One cellular target of the double-phosphorylated p68 is the activation of procaspase-8 in the DISC complex. DISC is assembled on the intercellular domain of the death receptor (Kim and Seol, 2003) . As p68 has not been detected to localize to the cell membrane by us and other laboratories (Nicol et al., 2000) , it is not known whether the Y593/595-phosphorylated p68 inhibits the DISC assembly or the procaspase-8 cleavage directly or indirectly. Another cellular target of the Y593/595-phosphorylated p68 is the expression of newly identified proapoptosis factor XAF1. Our data indicated that the Y593/595-phosphorylated p68 likely regulates the XAF1 at the transcriptional level judged by the changes of XAF1 mRNA (Figure 6a ). However, it is not known whether the phosphorylated p68 regulates the transcription of XAF1 gene directly or the regulatory effects are mediated via other cellular factor(s). Interestingly, regulation of XAF1 contributes only a partial reason for the apoptosis resistance mediated by the Y593/595-phosphorylated p68. It is generally believed that XIAP inhibits cell apoptosis by acting on caspase-3, -7 and -9. However, our data showed that the Y593/595-phosphorylated p68 also inhibits the activation of caspase-8 and that this inhibition is apparently XAF1 independent. An interesting observation in our studies is the effect of the Y593/595F on sensitizing both T98G and HCT-116R cells to TRAIL treatment. Expression of the mutant apparently has a very strong effect in addition to simple knockdown of p68, suggesting that the mutant is not a simple loss-of-function mutant. This notion is also supported by the experiments in which expression of the mutant without p68 knockdown also sensitizes T98G and HCT-116R to TRAIL treatment. There are two possible explanations. (1) The mutant has dominantnegative effects. It may compete with the wt protein for upstream/downstream molecules. (2) The Y593/595F may itself target different cellular factor(s), sensitizing otherwise resistant cells to apoptosis induction by a mechanism independent upon the wt p68. In any case, as the Y593/595F is able to reverse apoptosis resistance in the presence of the endogenous p68, the mutant has great potential for use in an anticancer therapy.
Materials and methods
Cell culture, plasmids and transfection Human T98G, LN-18, H460 and HCT-116 cells were purchased from ATCC (Manassas, VA, USA) and grown by following the vendor's instructions. All procedures for DNAs or RNAs transfections were the same as our previous reports (Yang et al., 2006) . The duplex RNA oligonucleotides for RNAi against p68 RNA helicase were as follows: sense, 5 0 -GCAAGUAGCUG CUGAAUAUUU-3 0 ; antisense, 5 0 -P AUAUUCAGCAGCUA CUUGCUU-3 0 , against c-Abl kinase and PDGFRa were siGENOME SMARTpool duplexes (Dharmacon, Lafayette, CO, USA). The various p68 mutants were generated using QuickChange site-directed mutagenesis (Stratagene, La Jolla, CA, USA) and confirmed by DNA sequencing.
Establishment of TRAIL-resistant cell lines TRAIL-resistant cell lines (H460R and HCT-116R) were derived from H460 and HCT-116 by the following procedure. TRAIL-sensitive H460 cells were initially exposed to 10 ng/ml TRAIL and then to gradually increased doses of TRAIL (up to 1000 ng/ml) over a 4-month period. The resultant TRAILresistant H460 cells were designated as H460R. In a slightly different way, HCT-116 cells were initially exposed to a relatively high dose of TRAIL at 200 ng/ml. The surviving cells were recovered and were again exposed to 200 ng/ml TRAIL and subsequent increased doses at 400, 600, 800 and 1000 ng/ ml. After approximately 1 month of selection, the resultant TRAIL-resistant cells were named HCT-116R. The TRAIL resistance cells were at least 30-50 times more resistant than parental cells. These resistant cell lines were routinely cultured in the presence of 100 ng/ml TRAIL. Subcellular extracts preparation, immunoprecipitation, immunoblot analyses and immunofluorescence staining and MALDI MS All nuclear extracts, cytoplasm or whole-cell extracts were made freshly after appropriate treatments (indicated in figures) by using nuclear extraction, cytoplasm and cell extracts kits (Activemotif, Carlsbad, CA, USA). Immunoprecipitation experiments and immunoblot analyses were performed as described in previous studies (Yang et al., 2006) . The experimental procedures for immunofluorescence staining and confocal imaging and for determination of the phosphorylation sites of immunopurified p68 from T98G cell extracts by MALDI MS were very similar to that described in our previous report (Yang et al., 2006) .
Cell viability (Trypan blue staining) and apoptosis assay
To estimate the percentage of apoptotic T98G cells after treatment with TRAIL, floating cells in the medium of each cell-culture plate were transferred to centrifuge tubes. After detachment of the adherent cells with trypsin, the cells were mixed with the corresponding floating cells before centrifugation. The cells were then stained with 0.4% Trypan blue, and the number of Trypan blue-positive and -negative cells were counted on a haemocytometer by light microscopy.
Apoptosis was determined using the APO-BRDU assay kit (BD Biosciences, Franklin Lake, NJ, USA). T98G or HCT-116 cells were transfected and treated with TRAIL as indicated. After treatment, cells were harvested in phosphate-buffered saline (PBS) and fixed in 1% paraformaldehyde for 15 min on ice. The cells were washed twice in PBS, followed by resuspension in 70% ethanol and stored at À201C. Cells were then treated with nucleotide mixture, terminal deoxynucleotidyl (TdT) transferase enzyme and bromolated uridine diphosphate (BrDU) for 24 h at 281C. Cells were washed, and fluorescence-conjugated anti-BrDU antibody was added for 1 h. Apoptosis was determined using a dual-laser FACScalibur (Becton-Dickinson, BD Biosceinces), after treating the cells with propidium iodide/RNAse solution for 30 min. The data were displayed using CELLQuest (BectonDickinson, BD Biosceinces).
